European Commission Approves Bristol-Myers Squibb’s Daklinza (daclatasvir) Across Multiple Genotypes for the Treatment of Chronic Hepatitis C Infection
|HCV genotype and patient population||Treatment||Duration|
|Genotype 1 or 4 without cirrhosis|
Daklinza + sofosbuvir
Consider prolongation of treatment to 24 weeks for patients with prior treatment including a NS3/4A protease inhibitor (see sections 4.4 and 5.1).
|Genotype 1 or 4 with compensated cirrhosis||Daklinza + sofosbuvir||24 weeks|
Shortening treatment to 12 weeks may be considered for previously untreated patients with cirrhosis and positive prognostic factors such as IL28B CC genotype and/or low baseline viral load.
Consider adding ribavirin for patients with very advanced liver disease or with other negative prognostic factors such as prior treatment experience.
|Genotype 3 with compensated cirrhosis and/or treatment experienced||Daklinza + sofosbuvir + ribavirin||24 weeks|
|Genotype 4||Daklinza + peginterferon alfa + ribavirin||24 weeks of Daklinza in combination with 24-48 weeks of peginterferon alfa and ribavirin.|
If the patient has HCV RNA undetectable at both treatment weeks 4 and 12, all 3 components of the regimen should be continued for a total duration of 24 weeks. If the patient achieves HCV RNA undetectable, but not at both treatment weeks 4 and 12, Daklinza should be discontinued at 24 weeks and peginterferon alfa and ribavirin continued for a total duration of 48 weeks.